Abstract:Background: Diabetes is prevalent among patients with hepatocellular carcinoma (HCC) and is associated with a poor prognosis. Although the hypoglycemic drug metformin has shown anti-tumor effects, its potential positive effect on patients with HCC and diabetes undergoing transarterial chemoembolization (TACE) remains unclear. Therefore, this study aimed to investigate the efficacy and safety of metformin in patients with HCC and type II diabetes who are receiving TACE. Materials and methods: This retrospective study involved 372 consecutive patients with HCC and type II diabetes across three medical centers between January 2014 and June 2021. All patients underwent TACE. Propensity score matching (PSM) was used to reduce selection bias. Cox proportional hazards regression was employed to compare all-cause death between the metformin and non-metformin groups, while competing risk regression was performed to assess cancer-specific death. Results: Among 372 patients included in the study, 208 patients (177 male patients and 31 female patients) with mean age 59.6 (10.3) years received metformin and 164 patients (139 male patients and 25 female patients) with mean age 60.3 (10.0) years did not. Before PSM, patients with metformin had significantly longer median overall survival (mOS) and median progression-free survival (mPFS) than those without metformin (mOS: 34 months, 95% CI: 25.6-42.4 vs. 20 months, 95% CI: 15.3-24.7; P<0.001; mPFS: 11 months, 95% CI: 9.3-12.7 vs. 8 months, 95% CI: 5.9-10.1; P<0.001). Similar results were observed after PSM. Multivariate regression analysis indicated that metformin was associated with a reduced risk of all-cause mortality (HR: 0.589, 95% CI: 0.454-0.763; P<0.001) and tumor progression (HR: 0.667, 95% CI: 0.526-0.845; P=0.001) before PSM. After excluding deaths related to other factors, metformin continued to demonstrate a reduction in cancer-specific mortality risk among the patients. Subgroup analysis further revealed that patients using metformin had lower all-cause mortality risk and tumor progression risk than those without metformin in most subgroups. Adverse event evaluation suggested that metformin could lead to elevated nausea incidence. Conclusion: Metformin may confer survival benefits to patients with HCC and type II diabetes undergoing TACE. Metformin may simultaneously address multiple aspects of treatment in these patients.

Metformin reduces the increased risk of oral squamous cell carcinoma recurrence in patients with type 2 diabetes mellitus: A cohort study with propensity score analyses

Association Between Metformin Use and Coronary Artery Calcification in Type 2 Diabetic Patients

Metformin Is Associated With Slightly Reduced Risk Of Colorectal Cancer And Moderate Survival Benefits In Diabetes Mellitus: A Meta-Analysis

Metformin Treatment Is Not Associated with Altered PD-L1 Expression in Diabetic Patients with Oral Squamous Cell Carcinoma

Metformin Use on Incidence and Oncologic Outcomes of Bladder Cancer Patients With T2DM: An Updated Meta-Analysis

Metformin Increases Survival in Hypopharyngeal Cancer Patients with Diabetes Mellitus: Retrospective Cohort Study and Cell-Based Analysis

Effect of metformin on hepatocellular carcinoma patients with type II diabetes receiving transarterial chemoembolization: a multicenter retrospective cohort study

Suppressive Effects of Metformin on Colorectal Adenoma Incidence and Malignant Progression

Impact of metformin use on the recurrence of hepatocellular carcinoma after initial liver resection in diabetic patients

Metformin effects on head and neck squamous carcinoma microenvironment: Window of opportunity trial

Reduced Risk Of Colorectal Cancer With Metformin Therapy In Patients With Type 2 Diabetes A Meta-Analysis

Transcriptional and H3K27ac related genome profiles in oral squamous cell carcinoma cells treated with metformin

Metformin use is associated with low risk of case fatality and disability rates in first-ever stroke patients with type 2 diabetes

Reduced Risk of Colorectal Cancer with Metformin Therapy in Patients with Type 2 Diabetes

Transarterial chemoembolization combined with metformin improves the prognosis of hepatocellular carcinoma patients with type 2 diabetes

The impact of metformin on mortality in patients with type 2 diabetes mellitus: a prospective cohort study

Metformin is Associated with Reduced Risk of Pancreatic Cancer in Patients with Type 2 Diabetes Mellitus: A Systematic Review and Meta-Analysis

Association Between Metformin Use and the Risk, Prognosis of Gynecologic Cancer

Metformin and reduced risk of hepatocellular carcinoma in diabetic patients: a meta-analysis.

Inhibition of Autophagy Promotes the Anti-Tumor Effect of Metformin in Oral Squamous Cell Carcinoma

Left thoracotomy for secondary revascularization of the circumflex coronary artery with late follow-up.